Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Earnings Results, Beats Estimates By $0.23 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) announced its quarterly earnings data on Monday. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23, FiscalAI reports. Vertex Pharmaceuticals had a return on equity of 24.41% and a net margin of 35.51%.The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the company earned $4.06 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 8.3% on a year-over-year basis.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Vertex reported strong Q1 results with $2.99 billion in product revenue (+8% YoY), reiterated full‑year guidance of $12.95–13.1 billion, ended Q1 with ~$13 billion in cash, and continued share repurchases — supporting near‑term financial momentum.
• Pivotal RAINIER interim Phase III data for povetacicept (Povi) in IgAN were described as “sparkling” — a 52% proteinuria reduction vs baseline (≈49.8% vs placebo), favorable safety, a 27‑day BLA filing turnaround, and initiation/advancement of PMN and gMG programs, underpinning a new renal franchise opportunity.
• Commercial momentum outside CF: CASGEVY has >500 patients initiated and delivered $43M in Q1 while securing reimbursement progress (e.g., Germany), and JOURNAVX surpassed 1M prescriptions written with 350k scripts in Q1 and expanded payer coverage (≈240M lives), supporting the company’s goal of >$500M non‑CF revenue in 2026.
• CF franchise remains core: ALYFTREK exceeded $1 billion cumulative revenue and recent label expansions for ALYFTREK/TRIKAFTA extend eligibility to ~95% of people with CF; next‑gen modulators (VX‑828, VX‑581, VX‑272) are progressing with a VX‑828 patient readout expected H2 2026.
• Vertex discontinued the VX‑522 mRNA program for patients who produce no CFTR protein due to lung inflammatory/tolerability issues, meaning the company will not advance this delivery approach for the hardest‑to‑treat CF patients and must pursue alternative modalities.

Vertex Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ:VRTX opened at $424.36 on Wednesday. The company has a 50 day moving average of $452.77 and a 200-day moving average of $449.59. The firm has a market cap of $107.94 billion, a P/E ratio of 25.17, a P/E/G ratio of 1.87 and a beta of 0.30. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $507.92.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Oppenheimer lifted their target price on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Truist Financial upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday. Evercore boosted their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, Sanford C. Bernstein dropped their target price on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $555.17.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 58,613 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the sale, the executive vice president owned 58,934 shares of the company’s stock, valued at $27,630,027.22. The trade was a 49.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Duncan Mckechnie sold 4,910 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the sale, the executive vice president owned 17,559 shares of the company’s stock, valued at $8,562,646.35. This trade represents a 21.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 81,853 shares of company stock valued at $38,479,135. 0.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VRTX. Motiv8 Investments LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $26,000. Swiss RE Ltd. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $28,000. Sfam LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $45,000. Kelleher Financial Advisors acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $46,000. Institutional investors own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Germany reimbursement for CASGEVY secures a payer agreement for eligible patients 12+ and opens sustainable access in a major EU market — a near‑term commercial catalyst for Vertex’s gene‑edited SCD/β‑thalassemia program. Read More.
• Positive Sentiment: Q1 beat on adjusted EPS and product revenue growth driven by cystic fibrosis launches and new products (management highlighted CF drug surge and contributions from newly launched therapies), supporting the company’s multi‑engine growth narrative. Read More.
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), which stabilizes expectations but offered limited upside vs. consensus — keeps guidance intact but is not a new positive catalyst. Read More.
• Neutral Sentiment: Analysts largely kept buy/outperform stances but trimmed price targets and models after the mixed quarter — suggests confidence in long‑term thesis but less near‑term conviction among some desks. Read More.
• Negative Sentiment: Insider selling by an EVP and a director was reported (sales executed under Rule 10b5‑1 plans), which can weigh on investor sentiment despite procedural context. Read More.
• Negative Sentiment: Shares pulled back after the mixed report — EPS beat but some metrics and commentary prompted profit‑taking and price‑target trims, driving the intraday weakness. Read More.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.